Biotech Values

[biomaven0]

If you take CLDX's name out and put a mid/big cap pharmas

But the difference is the size of the trial would have been at least double this one, and so the numbers would give a lot more confidence.

It is important to understand the triple-neg patients basically respond to nothing after their first treatment. So seeing some responses in this very heavily treated population is definitely encouraging. That said, it's not like this is a huge breakthrough - this is not a miracle drug.

Peter